

CorMedix Inc.  
Form SC 13G  
March 23, 2011

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**CORMEDIX INC.**

(Name of Issuer)

**COMMON STOCK**

(Title of Class of Securities)

**21900C100**

(CUSIP Number)

**December 31, 2010**

(Date of Event Which Requires Filing of this Statement)

David B. Clement, Esq.

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.

2500 Wachovia Capitol Center

150 Fayetteville Street

Raleigh, North Carolina 27601

(919) 821-1220

(Name, Address and Telephone Number  
of Person Authorized to Receive Notices and Communications)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

NAME OF REPORTING PERSON

**1**  
PharmaBio Development Inc.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

**2**  
(a)   
(b)

SEC USE ONLY

**3**

CITIZENSHIP OR PLACE OF ORGANIZATION

**4**  
North Carolina

SOLE VOTING POWER

**5**  
NUMBER OF 1,184,344 (1)

SHARED VOTING POWER

**6**  
SHARES BENEFICIALLY OWNED BY -0-

SOLE DISPOSITIVE POWER

**7**  
EACH REPORTING PERSON 1,184,344 (1)

SHARED DISPOSITIVE POWER

**8**  
WITH -0-

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

**9**  
1,184,344 (1)

**10** CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

o

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

10.0% (2)

**12** TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

<sup>1</sup> Includes 789,563 shares of common stock (the Common Stock ) of CorMedix Inc. (the Issuer ) beneficially owned by PharmaBio Development Inc. ( PharmaBio ) and warrants beneficially owned by PharmaBio that are exercisable for 394,781 shares of Common Stock. Therefore, the total shares of Common Stock of the Issuer beneficially owned by PharmaBio is 1,184,344.

<sup>2</sup> Calculated based on 11,408,274 shares of outstanding Common Stock of the Issuer on March 10, 2011, as reported in the Issuer s Annual Report on Form 10-K for the period ending December 31, 2010 and filed with the Securities and Exchange Commission on March 11, 2011.

---

CUSIP No. 21900C100 Schedule 13G Page 3 of 3 Pages  
**Item 1**

(a) Name of Issuer

CorMedix Inc. (the Issuer )

(b) Address of Issuer's Principal Executive Offices

745 Rt. 202-206  
Suite 303  
Bridgewater, New Jersey 08807

**Item 2**

(a) Name of Person Filing

PharmaBio Development Inc.

(b) Address of Principal Business Office or, if none, Residence

4208 Six Forks Road  
Suite 920  
Raleigh, NC 27609

(c) Citizenship

PharmaBio Development Inc. is a North Carolina corporation.

(d) Title of Class of Securities

Common stock, par value \$0.001 per share ( Common Stock ).

(e) CUSIP Number

21900C100

**Item 3**

Not Applicable

**Item 4** Ownership

(a) Amount Beneficially Owned

Includes 789,563 shares of common stock of the Issuer beneficially owned by PharmaBio and warrants beneficially owned by PharmaBio that are exercisable 394,781 shares of Common Stock. Therefore, the total shares of common stock of the Issuer beneficially owned by PharmaBio is 1,184,344.

**(b) Percent of Class:**

For PharmaBio, such 1,184,344 shares are 10.0% of the Issuer's common stock based on the 11,408,174 shares of outstanding Common Stock of the Issuer on March 10, 2011, as reported in the

---

CUSIP No. 21900C100 Schedule 13G Page 4 of 3 Pages  
Issuer's Annual Report on Form 10-K for the period ending December 31, 2010 and filed with the Securities and Exchange Commission on March 11, 2011.

(c) Number of Shares as to which such Person has:

PharmaBio:

(i) sole power to vote or to direct the vote: 1,184,344

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of: 1,184,344

(iv) shared power to dispose or to direct the disposition of: 0

**Item 5** Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]

**Item 6** Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

**Item 7** Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

**Item 8** Identification and Classification of Members of the Group

Not Applicable

**Item 9** Notice of Dissolution of Group

Not Applicable

**Item 10** Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 21900C100 Schedule 13G Page 5 of 3 Pages  
SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 23, 2011

**PHARMABIO DEVELOPMENT INC.**

By: /s/ Michael P. Troullis  
Name: Michael P. Troullis  
Title: President